ArticleFrontiers in cell and developmental biology2026
Integrative PANoptosis-focused omics analysis uncovers GSDMC as a candidate biomarker in breast cancer.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: PANoptosis, a form of programmed cell death involving crosstalk among pyroptosis, apoptosis, and necroptosis, has recently emerged as a key player in tumor progression and therapy resistance. Despite growing evidence linking PANoptosis to various cancers, the prognostic significance of PANoptosis-related genes (PANRGs) and their roles in breast cancer is not well defined. Investigating their relevance could reveal novel biomarkers for patient stratification and identify new therapeutic targets to overcome resistance to existing treatments. Methods: Multi-omics data from TCGA and GEO were analyzed to identify differentially expressed PANRGs. A prognostic signature was constructed via LASSO and multivariate Cox regression and validated in independent cohorts. Functional, microenvironmental, mutational, and drug sensitivity analyses were performed, with key findings validated experimentally. Results: A five-gene PANRG signature (AIFM1, GSDMC, IRF1, IL18, GZMB) effectively stratified patients into high- and low-risk groups. High-risk patients showed poorer overall survival, advanced TNM stages, immunosuppressive "cold tumor" microenvironments, metabolic reprogramming, higher TP53 mutation frequency, and increased resistance to chemotherapy but greater sensitivity to HER2/mTOR/EGFR-targeted therapies. Single-cell analysis revealed enhanced stromal communication and macrophage dynamics in high-risk patients. Experimental validation confirmed GSDMC upregulation in breast cancer tissues and its association with poor prognosis. Conclusion: This study developed and validated a novel PANoptosis-related prognostic signature for breast cancer, which predicts patient survival, immune landscape, metabolic features, and therapy response. The findings highlight the potential of PANRGs as biomarkers and therapeutic targets, providing a foundation for precision medicine in breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.